
Rocket Lab Slumps 57% on Neutron Delays, Yet Stifel Sees 133% Upside
Rocket Lab shares have fallen 57% from their 52-week high after a Neutron rocket test failure delayed its debut to Q4 2026. Despite the drop, Stifel analyst Erik Rasmussen maintains a $150 price target, implying more than a 100% gain. The bullish thesis relies on a record $2.36 billion backlog, strong defense contracts, and the pending Iridium acquisition, though investors remain wary of equity dilution and execution risks.



